The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy. A systematic review | Zendy

Martin Connock | Zendy; Emma Frew | Zendy; B. M. Evans | Zendy; Stirling Bryan | Zendy; Carole Cummins | Zendy; A Fry-Smith | Zendy; A. Li Wan Po | Zendy; Josie Sandercock | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy. A systematic review

Author(s) -

Martin Connock,

Emma Frew,

B. M. Evans,

Stirling Bryan,

Carole Cummins,

A Fry-Smith,

A. Li Wan Po,

Josie Sandercock

Publication year - 2006

Publication title -

health technology assessment

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.426

H-Index - 126

eISSN - 2046-4924

pISSN - 1366-5278

DOI - 10.3310/hta10070

Subject(s) - lamotrigine , medicine , oxcarbazepine , topiramate , epilepsy , levetiracetam , vigabatrin , gabapentin , randomized controlled trial , cost effectiveness , tiagabine , clinical trial , felbamate , dravet syndrome , pharmacoeconomics , pediatrics , intensive care medicine , anticonvulsant , psychiatry , carbamazepine , surgery , alternative medicine , risk analysis (engineering) , pathology

To examine the clinical effectiveness and cost-effectiveness of newer antiepileptic drugs (AEDs) for epilepsy in children: gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate and vigabatrin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research